Pascal Soriot, AstraZeneca CEO (Cole Burston/Bloomberg via Getty Images)

As­traZeneca pon­ders a Chi­na phar­ma spin­off to pro­tect it­self from geopo­lit­i­cal fall­out — FT

As se­nior gov­ern­ment of­fi­cials in the US war­i­ly look to sta­bi­lize rocky re­la­tions with Chi­na, one glob­al phar­ma gi­ant has been con­sid­er­ing a cor­po­rate re­struc­tur­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.